Table 2. In Vitro Biotransformation of Psilocybin and Twenty-Eight Novel Prodrug Derivatives (NPDs) upon Exposure to Human Serum and Human S9 and Microsomal Fractions after 120 min (μM; End Point Concentration).
| end
point in vitro psilocin concentration [μM] |
|||||
|---|---|---|---|---|---|
| NPDa | liver S9 fraction | liver microsomes | intestine S9 fraction | intestine microsomes | serum |
| PCB | 0.000 | 0.000 | 0.621 | 0.172 | 0.000 |
| ES01 | 1.950 | 2.718 | 0.114 | 0.041 | 1.097 |
| ES02 | 1.343 | 1.890 | 1.384 | 0.927 | 0.778 |
| ES03 | 1.244 | 2.554 | 0.533 | 0.786 | 0.450 |
| ES04 | 0.145 | 0.329 | 0.000 | 0.000 | 0.000 |
| ES05 | 0.689 | 1.310 | 0.000 | 0.018 | 2.010 |
| ES06 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| ES07 | 0.000 | 0.494 | 0.000 | 0.000 | 0.000 |
| ES08 | 0.656 | 1.659 | 0.195 | 0.887 | 0.000 |
| ES09 | 0.204 | 0.244 | 0.000 | 0.053 | 0.000 |
| ES10 | 0.451 | 0.919 | 0.166 | 0.241 | 3.148 |
| C01 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| C02 | 0.084 | 0.114 | 0.044 | 0.038 | 0.000 |
| C03 | 1.177 | 1.929 | 0.224 | 0.157 | 0.361 |
| C04 | 0.133 | 0.057 | 0.000 | 0.000 | 0.000 |
| C05 | 0.072 | 0.186 | 0.018 | 0.096 | 0.000 |
| T01 | 1.233 | 2.105 | 0.000 | 0.156 | 0.385 |
| T02 | 0.133 | 0.206 | 0.000 | 0.000 | 0.000 |
| ET01 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| EE01 | 0.012 | 0.073 | 0.018 | 0.043 | 0.000 |
| EE02 | 0.070 | 0.132 | 0.055 | 0.081 | 0.000 |
| EE03 | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 |
| EC01 | 0.186 | 0.056 | 0.000 | 0.000 | 0.000 |
| SE01 | 0.000 | 0.012 | 0.000 | 0.000 | 0.000 |
| SE02 | 0.000 | 0.000 | 0.000 | 0.000 | 0.142 |
| SE03 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| P02 | 0.073 | 0.000 | 0.000 | 0.076 | 0.069 |
| P03 | 0.011 | 0.000 | 0.000 | 0.000 | 0.000 |
| PA01 | 0.153 | 0.324 | 0.470 | 0.000 | 0.000 |
a
ES = ester; C = carbonate; T = thiocarbonate; ET = ether; EE = ether-esters; EC = ether-carbonate; SE = silyl-ether; P = phosphate; PA = phosphoramidate; and PCB = psilocybin.